TTTomoaki Tanaka

Tomoaki Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomoaki Tanaka has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 February 2012
      • Vol. 32  (2) , 615-8

    Intermediate oncological outcomes of percutaneous radiofrequency ablation for small renal tumors: initial experience.

    by Yujiro Nitta, Tomoaki Tanaka, Kazuya Morimoto, Tetsuya Makino, Noriaki Nishikawa, Kouichiro Tashiro, Toshihide Naganuma, Taro Iguchi, Toshiyuki Matsuoka, Tatsuya Nakatani

    For T1 stage incidental renal cell carcinoma (RCC), partial nephrectomy with or without laparoscopy is widely used on the basis of its nephron- sparing and minimally invasive nature. However, high-risk patients of advanced age, or with cardiovascular events are not often suitable candidates for surgery under general anesthesia. Percutaneous radiofrequency ablation (RFA) for mainly the treatment of these patients reportedly achieves satisfactory outcomes. We evaluated the clinical usefulness of this procedure in our initial cases. In total, 24 renal tumors in 22 patients who had been diagnosed with T1 stage RCC were treated by percutaneous RFA. A LeVeen Needle (Radiotherapeutics) was used with an RF3000 generator. The overlapping ablation method was applied to these tumors, which were larger than 3 cm or located close to the renal hilus. Dynamic contrast-enhanced computed tomography or magnetic resonance imaging was routinely carried out to evaluate the post-treatment state. Maximum tumor diameters ranged from 1.0 to 4.5 cm (mean=2.4 cm). The follow-up period was 1-61 months (mean=18 months) after RFA treatment. Contrast enhancement completely disappeared immediately after this procedure in 23 tumors, the one exception being a 4.5-cm tumor. The tumor recurrence-free and overall survival rates were 85% and 79%, respectively, at two years after RFA. Percutaneous RFA is a feasible option for the treatment of RCCs, particularly for those less than 3 cm in diameter.

  • Open Access

    Hyperbaric oxygen therapy for painful bladder syndrome/interstitial cystitis resistant to conventional treatments: long-term results of a case series in Japan

    by Tomoaki Tanaka, Yujiro Nitta, Kazuya Morimoto, Noriaki Nishikawa, Chikako Nishihara, Satoshi Tamada, Hidenori Kawashima, Tatsuya Nakatani

    There is no confirmed strategy for treating painful bladder syndrome/interstitial cystitis (PBS/IC) with unclear etiology. Therefore, a pilot study was carried out to evaluate the efficacy and safety of hyperbaric oxygen (HBO) therapy in treatment-resistant PBS/IC patients. HBO treatment (2.0 ATA for 60 minutes/day × 5 days/week for 2 or 4 weeks) was performed on 11 patients with severe symptoms that had not been improved by previous therapy regimens between December 2004 and July 2009. Seven of the 11 patients demonstrated persistent improvement in symptoms during the 12 months after HBO treatment. These responders demonstrated a decrease in the pelvic pain scale and urgency scale from 7.7 ± 1.0 and, 6.6 ± 0.9 to 3.4 ± 2.5 and 4.3 ± 2.4 after 12 months, respectively (p < 0.05). The total score of the interstitial cystitis symptom index and 24-hour urinary frequency demonstrated a significant sustained decrease from the baseline. Two responders, who received an additional course of HBO 12 and 13 months after initial treatment, respectively, did not suffer impairment for more than two years. There was one case of transient eustachian tube dysfunction and three cases of reversible exudative otitis media as a consequence of HBO treatment. HBO is a potent treatment for PBS/IC patients resistant to conventional therapy. It was well tolerated and provided maintained amelioration of pain, urgency and urinary frequency for at least 12 months.


    • 1 April 2011
      • Vol. 57  (4) , 209-12

    [Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].

    by Chikako Nishihara, Katsuyuki Kuratsukuri, Tomoaki Tanaka, Hidenori Kawashima, Tatsuya Nakatani

    The first case was in a 73-year-old man with macrohematuria. The second case was in a 59-year-old man with pollakiuria. Their serum prostate specific antigen levels were slightly elevated and urinary cytology was negative. Histological examination by prostatic needle biopsy and biopsy from bladder neck showed prostatic ductal adenocarcinoma. Clinical stage on computed tomography and magnetic resonance imaging was T4N0M0 in both cases. After 10-month maximal androgen blockade(MAB) and arterial chemotherapy using reservoir system, radiation therapy was performed. After that, low dose FP-chemotherapy(5-fluorouracil 600 mg/day, cisplatinum 10 mg/day) was performed for 28 days in the first case. At present, there are no signs of recurrence or metastasis in either case.


    • 30 May 2008
      • Vol. 28, 709-14

    Involvement of the estrogen receptor beta in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells.

    by Kentaro Matsumura, Tomoaki Tanaka, Hidenori Kawashima, Tatsuya Nakatani

    Dietary genistein, a phytoestrogen derived from soybean, has been suggested as a chemopreventive agent for prostate cancer. Genistein has been reported to exert its anticancer effects via a variety of functional pathways, but the upstream signaling of molecules regulated by genistein remains unclear. In this study, estrogen receptor (ER) beta involvement in genistein-induced expression of cell cycle inhibitors in PC-3 prostate cancer cells was investigated. The proliferation of PC-3 cells exposed to genistein was measured by the water-soluble tetrazolium salt (WST-1) proliferation assay. The expression of p21, p27 and ERbeta in the PC-3 cells was assessed by quantitative real-time reverse transcription-PCR. ERbeta silencing was performed using a small interfering RNA (siRNA). The transcriptional activity of the p21 promoter was determined by the luciferase reporter assay. Genistein caused marked inhibition of proliferative activity and induced the expression of p21 and ERbeta in the PC-3 cells. The siRNA against ERbeta suppressed the genistein-induced expression of p21 and reduced the transactivation activity of the p21 promoter induced by genistein. ERbeta is involved in genistein-induced expression of p21 in PC-3 cells.


    • 1 November 2006
      • Vol. 52  (11) , 895-7

    [Two cases of spermatic cord leiomyosarcoma].

    by Tetsuya Makino, Tomoko Hosono, Tomoaki Tanaka, Katsuyuki Kuratsukuri, Hidenori Kawashima, Tatsuya Nakatani

    A 72-year-old man and a 59-year-old man presented with painless hard swelling of left scrotal content. They underwent left high orchiectomy with clinical diagnosis of spermatic cord tumor. The pathological examination revealed leiomyosarcoma. The former had adjuvant radiation therapy locally. These are the 28th and 29th cases of spermatic cord leiomyosarcoma in Japan.

    • 1 June 2006
      • Vol. 52  (6) , 491-4

    [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].

    by Tomoaki Tanaka, Hidenori Kawashima, Katsuyuki Kuratsukuri, Kazunobu Sugimura, Tatsuya Nakatani

    Approximately 70% of patients with advanced prostate cancer have bone metastases, which are associated with considerable skeletal morbidity, accompanied by severe bone pain that requires narcotics or palliative radiation therapy, pathological fractures, spinal cord compression and hypercalcemia of malignancy (HCM), which consequentiy lower the patient's quality of life. Bisphosphonates, potent inhibitors of osteoclast activity and survival, therefore inhibiting osteoclast-mediated bone absorption, transiently palliative bone pain and decrease analgesic usage in patients who have hormone-refractory prostate cancer (HRPC) with bone metastases. Recently, a randomized controlled trial showed that a third-generation bisphosphonate, zoledronic acid reduced bone pain and skeletal-related events (SREs). In this manuscript, we reviwed the efficacy of bisphosphonates in HRPC with bone metastases from several clinical studies and discuss treatment of advanced prostate cancer with bisphosphonates.